Breast Cancer

, Volume 25, Issue 4, pp 470–478 | Cite as

Diagnosis, characteristics, and treatment of breast carcinomas within benign fibroepithelial tumors

  • Michiyo Saimura
  • Kenichiro Koga
  • Keisei Anan
  • Shoshu Mitsuyama
  • Sadafumi Tamiya
Original Article



Breast carcinoma arising in a benign fibroepithelial tumor is rare, and is usually discovered incidentally during examination of the breast mass.


We evaluated the clinicopathological features, treatment, and prognosis of seven women with breast carcinomas within benign fibroepithelial tumors, diagnosed and treated at a single institution between 2011 and 2015.


Seven women, aged 21–64 years, visited our hospital complaining of a breast mass detected by self-checking or screening examination. All patients had well-demarcated movable breast masses. Ultrasonography showed circumscribed masses suggesting benign tumors in all cases, and mammography revealed well-defined, high-density masses, with or without calcification. The masses progressed in two patients. A preoperative histological diagnosis of carcinoma was made following needle biopsy in four patients. Tumorectomy, breast-conserving surgery, and mastectomy were performed in three, two, and two patients, respectively. One patient underwent lymph node dissection and another underwent sentinel node biopsy. Histologically, the masses were diagnosed as invasive ductal carcinoma, ductal carcinoma in situ or lobular carcinoma in situ, arising in a benign phyllodes tumor, fibroadenoma, or fibroadenomatoid mastopathy. Lymph node metastasis was detected in two patients. There was no recurrence in any of the patients.


Although a carcinoma within a preexisting benign fibroepithelial tumor is extremely rare, it is important to be aware of the possibility of invasive and metastatic disease.


Breast carcinoma Benign fibroepithelial tumor Phyllodes tumor Fibroadenoma Fibroadenomatoid mastopathy 



We thank Susan Furness, Ph.D., from Edanz Group ( for editing a draft of this manuscript.

Compliance with ethical standards

Conflict of interest

The authors have no conflict of interest.


  1. 1.
    van Luijt PA, Heijnsdijk EA, Fracheboud J, Overbeek LI, Broeders MJ, Wesseling J, et al. The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening. Breast Cancer Res. 2016;18:47.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Yoshida M, Sekine S, Ogawa R, Yoshida H, Maeshima A, Kanai Y, et al. Frequent MED12 mutations in phyllodes tumours of the breast. Br J Cancer. 2015;112:1703–8.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Lim WK, Ong CK, Tan J, Thike AA, Ng CC, Rajasegaran V, et al. Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma. Nat Genet. 2014;46:877–80.CrossRefPubMedGoogle Scholar
  4. 4.
    Kuijper A, Buerger H, Simon R, Schaefer KL, Croonen A, Boecker W, et al. Analysis of the progression of fibroepithelial tumours of the breast by PCR-based clonality assay. J Pathol. 2002;197:575–81.CrossRefPubMedGoogle Scholar
  5. 5.
    Sawyer EJ, Hanby AM, Rowan AJ, Gillett CE, Thomas RE, Poulsom R, et al. The Wnt pathway, epithelial-stromal interactions, and malignant progression in phyllodes tumours. J Pathol. 2002;196:437–44.CrossRefPubMedGoogle Scholar
  6. 6.
    Ooe A, Takahara S, Sumiyoshi K, Yamamoto H, Shiba E, Kawai J. Preoperative diagnosis of ductal carcinoma in situ arising within a mammary fibroadenoma: a case report. Jpn J Clin Oncol. 2011;41:918–23.CrossRefPubMedGoogle Scholar
  7. 7.
    Nio Y, Iguchi C, Tsuboi K, Maruyama R. Ductal carcinoma in situ arising within a benign phyllodes tumor: a case report with a review of the literature. Oncol Lett. 2011;2:223–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Co M, Tse GM, Chen C, Wei J, Kwong A. Coexistence of ductal carcinoma within mammary phyllodes tumor: a review of 557 cases from a 20-year region-wide database in Hong Kong and Southern China. Clin Breast Cancer. 2017. Scholar
  9. 9.
    Sagara Y, Mallory MA, Wong S, Aydogan F, DeSantis S, Barry WT, et al. Survival benefit of breast surgery for low-grade ductal carcinoma in situ: a population-based cohort study. JAMA Surg. 2015;150:739–45.CrossRefPubMedGoogle Scholar
  10. 10.
    Sagara Y, Freedman RA, Vaz-Luis I, Mallory MA, Wong SM, Aydogan F, et al. Patient prognostic score and associations with survival improvement offered by radiotherapy after breast-conserving surgery for ductal carcinoma in situ: a population-based longitudinal cohort study. J Clin Oncol. 2016;34:1190–6.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010;2010:162–77.CrossRefPubMedGoogle Scholar
  12. 12.
    McCormick B, Winter K, Hudis C, Kuerer HM, Rakovitch E, Smith BL, et al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol. 2015;33:709–15.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2018

Authors and Affiliations

  1. 1.Department of SurgeryKitakyushu Municipal Medical CenterKitakyushuJapan
  2. 2.Department of PathologyKitakyushu Municipal Medical CenterKitakyushuJapan

Personalised recommendations